ArticleScientific reports2026
Long-term effects of short-term postoperative bromfenac on macular thickness after phacovitrectomy for idiopathic epiretinal membrane.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postoperative macular edema is a recognized complication following vitrectomy for idiopathic epiretinal membrane (ERM), particularly after combined phacovitrectomy. Topical nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit prostaglandin-mediated disruption of the blood-retinal barrier, but their long-term anatomical impact after ERM surgery has not been established. We retrospectively reviewed 282 eyes from 279 patients who underwent vitrectomy or phacovitrectomy for idiopathic ERM. Patients were categorized into an Early Use Group (topical bromfenac initiated within 4 weeks postoperatively, n = 91) and a Late/No Use Group (n = 191). The primary outcome was the change in central subfield macular thickness (CSMT) measured by OCT over 6 months. Longitudinal analysis was performed using a linear mixed-effects model (LME) with treatment-by-time interaction as the primary term. LME analysis revealed a significant treatment-by-time interaction for CSMT in the full cohort (F = 4.62, p = 0.003) and in the phacovitrectomy subgroup (F = 6.23, p < 0.001). The Early Use Group showed a significantly greater reduction in CSMT at 6 months (93.9 ± 56.2 μm) compared with the Late/No Use Group (76.6 ± 52.8 μm), with an estimated marginal mean difference of approximately 14-15 μm maintained at all post-baseline time points (p ≤ 0.006). For logMAR BCVA, a significant treatment-by-time interaction was also observed (F = 2.68, p = 0.046): the Early Use Group showed significantly faster visual recovery at 1 month (p = 0.016), but both groups converged to equivalent visual acuity by 6 months (p = 0.305). Early postoperative bromfenac within 4 weeks of phacovitrectomy for ERM significantly reduces macular thickness, and this anatomical benefit is durably maintained for at least 6 months, along with accelerated visual acuity recovery at 1 month. These findings raise the hypothesis that prostaglandin-mediated vascular permeability in the early postoperative period may influence long-term macular remodeling; however, this remains speculative, as direct evidence of permeability changes was not assessed in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.